Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2024, 8 (2), s366. https://doi.org/10.25251/skin.8.supp.366.